Inovio Pharmaceuticals, Inc. (Nasdaq: INO) announced the dosing of the first subject in its multi-center phase I trial to evaluate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE